Journal
VACCINES
Volume 9, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9101140
Keywords
SARS-CoV-2; BNT162b2 vaccine; ChAdOx1 nCoV-19 vaccine; antibody response; teriflunomide
Categories
Ask authors/readers for more resources
The study demonstrated that a MS patient treated with teriflunomide showed a strong humoral response after receiving a ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen, indicating that the medication did not hinder the development of an effective immune response to the vaccine.
Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of prime-boost (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and a second one of an mRNA-based vaccine in such patients has not yet been completed. Here, we present the anti-spike protein S humoral response, including the neutralizing antibody response, in a 54-year-old MS patient who had been treated with teriflunomide for the past 2 years and who received a heterologous ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen. The results showed a very strong anti-S IgG response and a good neutralizing antibody response. These results show that teriflunomide did not prevent the development of a satisfactory humoral response in this MS patient after vaccination with a ChAdOx1 nCoV-19/ BNT162b2 prime-boost protocol.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available